Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 42 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

7 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

12 recruiting

Enrollment Performance

Analytics

Phase 2

29(72.5%)

Phase 4

5(12.5%)

Phase 1

2(5.0%)

Phase 3

2(5.0%)

N/A

2(5.0%)

40Total

Phase 2(29)

Phase 4(5)

Phase 1(2)

Phase 3(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (42)

Showing 20 of 42 trials

NCT07528898Phase 2Not Yet Recruiting

Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.

Role: collaborator

NCT07492394Phase 2Recruiting

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

Role: collaborator

NCT07490210Phase 2Not Yet Recruiting

Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer

Role: collaborator

NCT06239727Phase 3Recruiting

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Role: collaborator

NCT07382713Phase 2Not Yet Recruiting

Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer

Role: collaborator

NCT06177522Phase 2Not Yet Recruiting

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Role: collaborator

NCT06348264Phase 2Recruiting

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Role: collaborator

NCT05660785Phase 2Completed

Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

Role: collaborator

NCT06818851Phase 4Recruiting

The Effects of Henagliflozin on Glucose Fluctuation and Immunosenescence in Type 2 Diabetes Patients on Insulin Therapy

Role: collaborator

NCT07062328Phase 2Not Yet Recruiting

A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC

Role: collaborator

NCT06827717Phase 2Recruiting

Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma

Role: collaborator

NCT05294055Phase 2Recruiting

Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

Role: collaborator

NCT06208462Phase 2Recruiting

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Role: collaborator

NCT06796803Phase 2Not Yet Recruiting

Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

Role: collaborator

NCT06762223Phase 4Not Yet Recruiting

Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM

Role: collaborator

NCT05613478Phase 3Recruiting

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

Role: collaborator

NCT06607107Phase 2Recruiting

mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria

Role: collaborator

NCT06475417Phase 2Recruiting

Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer